Breaking News Instant updates and real-time market news.

ADAP

Adaptimmune

$6.97

0.05 (0.72%)

16:35
10/05/16
10/05
16:35
10/05/16
16:35

Adaptimmune to present poster presentation of udated data on NY-ESO SPEAR

Adaptimmune Therapeutics announced that it will present a poster presentation of updated data on its lead clinical program, an NY-ESO SPEAR, Specific Peptide Enhanced Affinity Receptor, T-cell therapy, in patients with synovial sarcoma at the European Society for Medical Oncology, ESMO, 2016 Congress. This meeting will take place at the Bella Center exhibition center in Copenhagen, Denmark on October 7 through 11.

  • 07

    Oct

ADAP Adaptimmune
$6.97

0.05 (0.72%)

02/25/16
02/25/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boston Scientific (BSX) initiated with a Buy at SunTrust by analyst Bruce Nudell, who expects an organic growth accelerating through 2018 driven by structural heart sales and core market stabilization. 2. Kite Pharma (KITE) initiated with a Buy, with analyst Robyn Karnauskas saying that Kite's technology could be the first to market and its data in the largest blood cancer market look similar to competition. The analyst also started Juno Therapeutics (JUNO) and Adaptimmune (ADAP) with Buy ratings. 3. Insulet (PODD) initiated with a Sell at Empire by analyst Cathy Reese, who said the company has several issues with its OmniPod System that will not be remedied with planned upgrades. 4. Biogen (BIIB) initiated with a Buy at Citi. 5. Crown Castle (CCI) initiated with a Buy at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/04/16
LEER
08/04/16
NO CHANGE
LEER
Outperform
Adaptimmune partial clinical hold on planned trial 'surprising,' says Leerink
Leerink analyst Michael Schmidt sees the announced partial clinical hold on Adaptimmune's liposarcoma study as "surprising" and notes that it introduces some additional risk. However, the analyst says the news does not "fundamentally" change his investment thesis on Adaptimmune as he expects a rapid resolution. Schmidt reiterates an Outperform rating on the shares.
08/26/16
SBSH
08/26/16
NO CHANGE
SBSH
Buy
Adaptimmune partial clinical hold may be lifted within weeks, says Citi
Citi analyst Robyn Karnauskas said that after traveling with several members of Adaptimmune's management team, including its CEO and CFO, she came away feeling that their TCR platform remains in the lead despite delays. The FDA's partial clinical hold in myxoid round cell liposarcoma, or MRCLS, was not related to safety or efficacy of the product and Karnauskas sees the potential for the FDA to possibly reverse the partial clinical hold within a few weeks, she tells investors. Citi keeps a Buy rating on Adaptimmune shares.
09/30/16
RAJA
09/30/16
INITIATION
Target $16
RAJA
Outperform
Adaptimmune initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Adaptimmune with a Buy and a $16 price target saying it is a leading player in the engineered T cell receptor therapy space, with a growing product portfolio concentrating primarily in the solid tumor market.

TODAY'S FREE FLY STORIES

EHC

Encompass Health

$51.31

-0.15 (-0.29%)

06:11
01/17/18
01/17
06:11
01/17/18
06:11
Initiation
Encompass Health initiated  »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$176.19

-0.9 (-0.51%)

06:09
01/17/18
01/17
06:09
01/17/18
06:09
Downgrade
Apple rating change  »

Longbow downgrades Apple…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

SPG

Simon Property

$165.04

-0.47 (-0.28%)

, SBUX

Starbucks

$60.56

0.16 (0.26%)

06:09
01/17/18
01/17
06:09
01/17/18
06:09
Periodicals
Simon, Starbucks reach settlement over Teavana closures, WSJ reports »

Simon Property Group…

SPG

Simon Property

$165.04

-0.47 (-0.28%)

SBUX

Starbucks

$60.56

0.16 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 31

    Jan

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

, GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

06:08
01/17/18
01/17
06:08
01/17/18
06:08
Hot Stocks
YouTube implements additional requirements for YouTube Partner Program »

In a blog post, Neal…

GOOG

Alphabet

$1,121.76

-0.5 (-0.04%)

GOOGL

Alphabet Class A

$1,130.70

0.05 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 23

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 18

    Mar

TPC

Tutor Perini

$27.00

-0.5 (-1.82%)

06:07
01/17/18
01/17
06:07
01/17/18
06:07
Hot Stocks
Tutor Perini subsidiary awarded three new projects for $67M »

Tutor Perini's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:05
01/17/18
01/17
06:05
01/17/18
06:05
Earnings
Orbotech sees FY18 revenue up 12%-14% »

Sees 12-14% revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:04
01/17/18
01/17
06:04
01/17/18
06:04
Earnings
Breaking Earnings news story on Orbotech »

Orbotech sees Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRN

Amarin

$4.11

-0.14 (-3.29%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
Amarin initiates clinical development of Vascepa in China »

Amarin's partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Downgrade
NuVasive rating change  »

Wells Fargo sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.55 (-2.93%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
GE: Peter Stracar to succeed Mark Hutchinson as President and CEO of GE Europe »

GE announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

KL

Kirkland Lake Gold

$16.74

0.62 (3.85%)

06:03
01/17/18
01/17
06:03
01/17/18
06:03
Hot Stocks
Kirkland Lake Gold sees FY18 production growth to over 620,000 ounces »

Highlights of 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ORBK

Orbotech

$51.47

0.38 (0.74%)

06:02
01/17/18
01/17
06:02
01/17/18
06:02
Earnings
Orbotech reports preliminary Q4 revenue of about $256M, consensus $250.16M »

Gross margin is expected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$24.66

-0.75 (-2.95%)

06:01
01/17/18
01/17
06:01
01/17/18
06:01
Periodicals
Twitter sued by TWiT for breach of contract, infringement, TechCrunch reports »

Twitter is being sued by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

SLGN

Silgan Holdings

$29.29

-0.23 (-0.78%)

, CCK

Crown Holdings

$57.79

-0.31 (-0.53%)

05:58
01/17/18
01/17
05:58
01/17/18
05:58
Downgrade
Silgan Holdings, Crown Holdings, Berry Global, Ball Corp. rating change  »

Silgan Holdings…

SLGN

Silgan Holdings

$29.29

-0.23 (-0.78%)

CCK

Crown Holdings

$57.79

-0.31 (-0.53%)

BERY

Berry Global

$59.13

-1.1 (-1.83%)

BLL

Ball Corp.

$38.39

0.49 (1.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 07

    Feb

  • 08

    Feb

ABB

ABB

$28.07

-0.02 (-0.07%)

05:55
01/17/18
01/17
05:55
01/17/18
05:55
Downgrade
ABB rating change  »

ABB downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

IFF

International Flavors

$152.54

-1.16 (-0.75%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Upgrade
International Flavors rating change  »

International Flavors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

05:54
01/17/18
01/17
05:54
01/17/18
05:54
Downgrade
Adient rating change  »

Adient downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AEP

American Electric

$67.50

0.04 (0.06%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Upgrade
American Electric rating change  »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$116.64

-1.53 (-1.29%)

05:53
01/17/18
01/17
05:53
01/17/18
05:53
Downgrade
PPG rating change  »

PPG downgraded to Neutral…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

NBR

Nabors Industries

$8.23

0.04 (0.49%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Nabors Industries rating change  »

Nabors Industries resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

ETH

Ethan Allen

$28.15

-0.5 (-1.75%)

05:52
01/17/18
01/17
05:52
01/17/18
05:52
Downgrade
Ethan Allen rating change  »

Ethan Allen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

QTS

QTS Realty Trust

$52.47

0.82 (1.59%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
QTS Realty Trust rating change  »

QTS Realty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LQ

La Quinta

$18.44

-0.03 (-0.16%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Upgrade
La Quinta rating change  »

La Quinta upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASND

Ascendis Pharma

$47.60

1.02 (2.19%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Recommendations
Ascendis Pharma analyst commentary  »

Ascendis Pharma price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

05:50
01/17/18
01/17
05:50
01/17/18
05:50
Downgrade
Shell Midstream rating change  »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.